Articolul precedent |
Articolul urmator |
787 3 |
Ultima descărcare din IBN: 2022-01-15 19:04 |
SM ISO690:2012 NEGRYA, S., EFREMENKOVA, O., ARTEMYEV, M., SIZOVA, S., OLEINIKOV, V., ALEXANDROVA, L.. Novel conjugates <modified nucleoside – nanoparticle> to suppress the growth of superbugs. In: NANO: - 2019: Limits of Nanoscience and Nanotechnologies, Ed. 2019, 24-27 septembrie 2019, Chişinău. Chișinău, Republica Moldova: 2019, p. 64. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
NANO 2019 | |
Conferința "SPINTECH Summer school “S/F Hybrid Structures for Spintronics”" 2019, Chişinău, Moldova, 24-27 septembrie 2019 | |
|
|
Pag. 64-64 | |
Descarcă PDF | |
Rezumat | |
Nowadays practically all pathogenic bacteria and viruses have developed resistance to most clinically important medicinal preparations, hence, there is a need in new drugs acting on new targets and being active against superbugs - resistant strains of pathogens [1]. Recently we have synthesized 2’-deoxypyrimidine nucleoside derivatives bearing extended alkyloxymethyl or alkyl(1,2,3-triazol-1-yl)methyl substituents at С-5 position and demonstrated their effective bacteriostatic activity against two Mycobacterium tuberculosis strains [2] as well as against a set of Gram-positive bacteria [3]. However, the nucleosides with large hydrophobic fragments are insoluble in water, thus, limiting the biological investigations. To solve this problem, a linker group was introduced for coupling a nucleoside moiety to a nanoparticle. At the same time, we have developed fundamentally new nanostructures of the type “Plates” with both positive and negative surface charge [5] with uniquely high optical properties (narrow fluorescence peak, high extinction, high efficiency of two-photon excitation) and offered an efficient method for obtaining conjugates [nucleoside-nanoparticle]. To study the effect of nanostructures on bacterial cells were selected bacteria that differ in shape, structure and thickness of the cell wall. Herein we will present a new approach for transporting medicinal agents into bacterial cells to their targets, namely, the preparation of conjugates of biologically active nucleosides with nanoparticles. |
|
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-92954</cfResPublId> <cfResPublDate>2019</cfResPublDate> <cfStartPage>64</cfStartPage> <cfISBN></cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/92954</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Novel conjugates <modified nucleoside – nanoparticle> to suppress the growth of superbugs</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Nowadays practically all pathogenic bacteria and viruses have developed resistance to most clinically important medicinal preparations, hence, there is a need in new drugs acting on new targets and being active against superbugs - resistant strains of pathogens [1]. Recently we have synthesized 2’-deoxypyrimidine nucleoside derivatives bearing extended alkyloxymethyl or alkyl(1,2,3-triazol-1-yl)methyl substituents at С-5 position and demonstrated their effective bacteriostatic activity against two Mycobacterium tuberculosis strains [2] as well as against a set of Gram-positive bacteria [3]. However, the nucleosides with large hydrophobic fragments are insoluble in water, thus, limiting the biological investigations. To solve this problem, a linker group was introduced for coupling a nucleoside moiety to a nanoparticle. At the same time, we have developed fundamentally new nanostructures of the type “Plates” with both positive and negative surface charge [5] with uniquely high optical properties (narrow fluorescence peak, high extinction, high efficiency of two-photon excitation) and offered an efficient method for obtaining conjugates [nucleoside-nanoparticle]. To study the effect of nanostructures on bacterial cells were selected bacteria that differ in shape, structure and thickness of the cell wall. Herein we will present a new approach for transporting medicinal agents into bacterial cells to their targets, namely, the preparation of conjugates of biologically active nucleosides with nanoparticles.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-71798</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-71799</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-71800</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-71801</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-71802</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-71803</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-71798</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71798-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Negrya</cfFamilyNames> <cfFirstNames>S.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-71799</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71799-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Efremenkova</cfFamilyNames> <cfFirstNames>O.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-71800</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71800-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Artemyev</cfFamilyNames> <cfFirstNames>M.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-71801</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71801-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Sizova</cfFamilyNames> <cfFirstNames>S.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-71802</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71802-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Oleinikov</cfFamilyNames> <cfFirstNames>V.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-71803</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-71803-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2019T24:00:00</cfStartDate> <cfFamilyNames>Alexandrova</cfFamilyNames> <cfFirstNames>L.</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>